drugset / Trial / NCT00553449

Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD) Patients With Night-time Heartburn Symptoms.

NCT00553449

Phase 3 Completed 48 enrolled Janssen-Ortho Inc., Canada
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effect of each of the rabeprazole treatment regimens on nocturnal heartburn symptoms.

Timeline

Start
2004-07
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Rabeprazole Small molecule 10 mg
Subject Rabeprazole Small molecule 20 mg